CANCER 2015

A Prospective, Population-based Cancer Genome Cohort (#231)

So Young Moon, John Parisot, Huiling Xu, Mark Lucas, Stephen Wong, David Choong, Chris McEvoy, Ravikiran Vedururu, Kate Crough, Kristy Barnes-Cullen, Emma Galligan, Nicole Ng, Tina Smith, Lea-Anne Harrison, Marcelle Hennig, Sandra Robinson, Jenny MacIndoe, Rachel Osborne, The KConFab Investigators, The MMP Investigators & 10 others Paula Lorgelly, Lara Lipton, John McNeil, David Ashley, Theresa Hayes, Gary Richardson, Anthony Bell, Andrew Fellowes, David Thomas, Stephen B. Fox

Research output: Contribution to conferencePosterOtherpeer-review

Abstract

Cancer 2015 is a prospective, population-based cancer genomic cohort study. The study aims to test a new model of cancer diagnosis and treatment, with a specific focus on integrating molecular pathology into routine cancer diagnosis, treatment and research. Newly diagnosed adult patients with solid cancers are recruited into the cohort across five hospitals in Victoria, Australia, with the dataset collected including clinical, molecular pathology, health outcomes, health resource use, and health-related quality of life data. In Phase 1, we have established an upscalable cohort of 1000 patients with all mainstream solid cancer types as well as rare cancers. Molecular testing was performed using targeted exon sequencing. In Phase 2, additional 2000 patients have been recruited and protocols have been further developed to facilitate timely retrieval of specimen, molecular testing and real-time reporting. To date, over 360 real-time reports with identification of potential actionable mutations have been issued, and the utilisation of genomic data for personalised treatment and/or for enrolment into clinical trials is to be investigated when more mature data becomes available toward the end of Phase 2. In addition to its clinical utility, Cancer 2015 serves as a comprehensive cancer database providing valuable resources for cancer research. The Cancer 2015 database currently contains approximately 3000 patients and provides comprehensive demographic, epidemiological, and clinico-pathological information including previous/family cancer history, syndromes, smoking status, tumour site, stage, morphology, treatment details, and mutational data as well as health resource use and health-related quality of life data which are collected at diagnosis, 6 months after diagnosis, and yearly thereafter. The Cancer 2015 bio-specimen and data are available to the cancer research community through a formal application. More details of Cancer 2015 mutational profiles are outlined in the abstract entitled “Cancer genetic mutation profiling in Cancer 2015 cohort” (abstract #42378). Information about the available resources and the access process is available at http://www.cancer2015.org.
Original languageEnglish
Number of pages1
Publication statusPublished - 2017
EventLorne Cancer Conference 2017 - Mantra Lorne Hotel, Lorne, Australia
Duration: 9 Feb 201711 Feb 2017
Conference number: 29th

Conference

ConferenceLorne Cancer Conference 2017
CountryAustralia
CityLorne
Period9/02/1711/02/17

Cite this

Moon, S. Y., Parisot, J., Xu, H., Lucas, M., Wong, S., Choong, D., ... Fox, S. B. (2017). CANCER 2015: A Prospective, Population-based Cancer Genome Cohort (#231). Poster session presented at Lorne Cancer Conference 2017, Lorne, Australia.
Moon, So Young ; Parisot, John ; Xu, Huiling ; Lucas, Mark ; Wong, Stephen ; Choong, David ; McEvoy, Chris ; Vedururu, Ravikiran ; Crough, Kate ; Barnes-Cullen, Kristy ; Galligan, Emma ; Ng, Nicole ; Smith, Tina ; Harrison, Lea-Anne ; Hennig, Marcelle ; Robinson, Sandra ; MacIndoe, Jenny ; Osborne, Rachel ; Investigators, The KConFab ; MMP Investigators, The ; Lorgelly, Paula ; Lipton, Lara ; McNeil, John ; Ashley, David ; Hayes, Theresa ; Richardson, Gary ; Bell, Anthony ; Fellowes, Andrew ; Thomas, David ; Fox, Stephen B. / CANCER 2015 : A Prospective, Population-based Cancer Genome Cohort (#231). Poster session presented at Lorne Cancer Conference 2017, Lorne, Australia.1 p.
@conference{7a123cca2dc44de2890e60010969e718,
title = "CANCER 2015: A Prospective, Population-based Cancer Genome Cohort (#231)",
abstract = "Cancer 2015 is a prospective, population-based cancer genomic cohort study. The study aims to test a new model of cancer diagnosis and treatment, with a specific focus on integrating molecular pathology into routine cancer diagnosis, treatment and research. Newly diagnosed adult patients with solid cancers are recruited into the cohort across five hospitals in Victoria, Australia, with the dataset collected including clinical, molecular pathology, health outcomes, health resource use, and health-related quality of life data. In Phase 1, we have established an upscalable cohort of 1000 patients with all mainstream solid cancer types as well as rare cancers. Molecular testing was performed using targeted exon sequencing. In Phase 2, additional 2000 patients have been recruited and protocols have been further developed to facilitate timely retrieval of specimen, molecular testing and real-time reporting. To date, over 360 real-time reports with identification of potential actionable mutations have been issued, and the utilisation of genomic data for personalised treatment and/or for enrolment into clinical trials is to be investigated when more mature data becomes available toward the end of Phase 2. In addition to its clinical utility, Cancer 2015 serves as a comprehensive cancer database providing valuable resources for cancer research. The Cancer 2015 database currently contains approximately 3000 patients and provides comprehensive demographic, epidemiological, and clinico-pathological information including previous/family cancer history, syndromes, smoking status, tumour site, stage, morphology, treatment details, and mutational data as well as health resource use and health-related quality of life data which are collected at diagnosis, 6 months after diagnosis, and yearly thereafter. The Cancer 2015 bio-specimen and data are available to the cancer research community through a formal application. More details of Cancer 2015 mutational profiles are outlined in the abstract entitled “Cancer genetic mutation profiling in Cancer 2015 cohort” (abstract #42378). Information about the available resources and the access process is available at http://www.cancer2015.org.",
author = "Moon, {So Young} and John Parisot and Huiling Xu and Mark Lucas and Stephen Wong and David Choong and Chris McEvoy and Ravikiran Vedururu and Kate Crough and Kristy Barnes-Cullen and Emma Galligan and Nicole Ng and Tina Smith and Lea-Anne Harrison and Marcelle Hennig and Sandra Robinson and Jenny MacIndoe and Rachel Osborne and Investigators, {The KConFab} and {MMP Investigators}, The and Paula Lorgelly and Lara Lipton and John McNeil and David Ashley and Theresa Hayes and Gary Richardson and Anthony Bell and Andrew Fellowes and David Thomas and Fox, {Stephen B.}",
year = "2017",
language = "English",
note = "Lorne Cancer Conference 2017 ; Conference date: 09-02-2017 Through 11-02-2017",

}

Moon, SY, Parisot, J, Xu, H, Lucas, M, Wong, S, Choong, D, McEvoy, C, Vedururu, R, Crough, K, Barnes-Cullen, K, Galligan, E, Ng, N, Smith, T, Harrison, L-A, Hennig, M, Robinson, S, MacIndoe, J, Osborne, R, Investigators, TKC, MMP Investigators, T, Lorgelly, P, Lipton, L, McNeil, J, Ashley, D, Hayes, T, Richardson, G, Bell, A, Fellowes, A, Thomas, D & Fox, SB 2017, 'CANCER 2015: A Prospective, Population-based Cancer Genome Cohort (#231)' Lorne Cancer Conference 2017, Lorne, Australia, 9/02/17 - 11/02/17, .

CANCER 2015 : A Prospective, Population-based Cancer Genome Cohort (#231). / Moon, So Young; Parisot, John; Xu, Huiling; Lucas, Mark; Wong, Stephen; Choong, David; McEvoy, Chris ; Vedururu, Ravikiran; Crough, Kate; Barnes-Cullen, Kristy ; Galligan, Emma; Ng, Nicole; Smith, Tina; Harrison, Lea-Anne ; Hennig, Marcelle ; Robinson, Sandra; MacIndoe, Jenny; Osborne, Rachel; Investigators, The KConFab ; MMP Investigators, The ; Lorgelly, Paula; Lipton, Lara; McNeil, John; Ashley, David; Hayes, Theresa; Richardson, Gary; Bell, Anthony; Fellowes, Andrew; Thomas, David; Fox, Stephen B.

2017. Poster session presented at Lorne Cancer Conference 2017, Lorne, Australia.

Research output: Contribution to conferencePosterOtherpeer-review

TY - CONF

T1 - CANCER 2015

T2 - A Prospective, Population-based Cancer Genome Cohort (#231)

AU - Moon, So Young

AU - Parisot, John

AU - Xu, Huiling

AU - Lucas, Mark

AU - Wong, Stephen

AU - Choong, David

AU - McEvoy, Chris

AU - Vedururu, Ravikiran

AU - Crough, Kate

AU - Barnes-Cullen, Kristy

AU - Galligan, Emma

AU - Ng, Nicole

AU - Smith, Tina

AU - Harrison, Lea-Anne

AU - Hennig, Marcelle

AU - Robinson, Sandra

AU - MacIndoe, Jenny

AU - Osborne, Rachel

AU - Investigators, The KConFab

AU - MMP Investigators, The

AU - Lorgelly, Paula

AU - Lipton, Lara

AU - McNeil, John

AU - Ashley, David

AU - Hayes, Theresa

AU - Richardson, Gary

AU - Bell, Anthony

AU - Fellowes, Andrew

AU - Thomas, David

AU - Fox, Stephen B.

PY - 2017

Y1 - 2017

N2 - Cancer 2015 is a prospective, population-based cancer genomic cohort study. The study aims to test a new model of cancer diagnosis and treatment, with a specific focus on integrating molecular pathology into routine cancer diagnosis, treatment and research. Newly diagnosed adult patients with solid cancers are recruited into the cohort across five hospitals in Victoria, Australia, with the dataset collected including clinical, molecular pathology, health outcomes, health resource use, and health-related quality of life data. In Phase 1, we have established an upscalable cohort of 1000 patients with all mainstream solid cancer types as well as rare cancers. Molecular testing was performed using targeted exon sequencing. In Phase 2, additional 2000 patients have been recruited and protocols have been further developed to facilitate timely retrieval of specimen, molecular testing and real-time reporting. To date, over 360 real-time reports with identification of potential actionable mutations have been issued, and the utilisation of genomic data for personalised treatment and/or for enrolment into clinical trials is to be investigated when more mature data becomes available toward the end of Phase 2. In addition to its clinical utility, Cancer 2015 serves as a comprehensive cancer database providing valuable resources for cancer research. The Cancer 2015 database currently contains approximately 3000 patients and provides comprehensive demographic, epidemiological, and clinico-pathological information including previous/family cancer history, syndromes, smoking status, tumour site, stage, morphology, treatment details, and mutational data as well as health resource use and health-related quality of life data which are collected at diagnosis, 6 months after diagnosis, and yearly thereafter. The Cancer 2015 bio-specimen and data are available to the cancer research community through a formal application. More details of Cancer 2015 mutational profiles are outlined in the abstract entitled “Cancer genetic mutation profiling in Cancer 2015 cohort” (abstract #42378). Information about the available resources and the access process is available at http://www.cancer2015.org.

AB - Cancer 2015 is a prospective, population-based cancer genomic cohort study. The study aims to test a new model of cancer diagnosis and treatment, with a specific focus on integrating molecular pathology into routine cancer diagnosis, treatment and research. Newly diagnosed adult patients with solid cancers are recruited into the cohort across five hospitals in Victoria, Australia, with the dataset collected including clinical, molecular pathology, health outcomes, health resource use, and health-related quality of life data. In Phase 1, we have established an upscalable cohort of 1000 patients with all mainstream solid cancer types as well as rare cancers. Molecular testing was performed using targeted exon sequencing. In Phase 2, additional 2000 patients have been recruited and protocols have been further developed to facilitate timely retrieval of specimen, molecular testing and real-time reporting. To date, over 360 real-time reports with identification of potential actionable mutations have been issued, and the utilisation of genomic data for personalised treatment and/or for enrolment into clinical trials is to be investigated when more mature data becomes available toward the end of Phase 2. In addition to its clinical utility, Cancer 2015 serves as a comprehensive cancer database providing valuable resources for cancer research. The Cancer 2015 database currently contains approximately 3000 patients and provides comprehensive demographic, epidemiological, and clinico-pathological information including previous/family cancer history, syndromes, smoking status, tumour site, stage, morphology, treatment details, and mutational data as well as health resource use and health-related quality of life data which are collected at diagnosis, 6 months after diagnosis, and yearly thereafter. The Cancer 2015 bio-specimen and data are available to the cancer research community through a formal application. More details of Cancer 2015 mutational profiles are outlined in the abstract entitled “Cancer genetic mutation profiling in Cancer 2015 cohort” (abstract #42378). Information about the available resources and the access process is available at http://www.cancer2015.org.

M3 - Poster

ER -

Moon SY, Parisot J, Xu H, Lucas M, Wong S, Choong D et al. CANCER 2015: A Prospective, Population-based Cancer Genome Cohort (#231). 2017. Poster session presented at Lorne Cancer Conference 2017, Lorne, Australia.